Latest news with #Precision
Yahoo
11-06-2025
- Entertainment
- Yahoo
Corky's missing guitar
Jun. 11—Daughter continues search for bass that was stolen in 2014 When Summer Lambert's father passed away, one thing that weighed on her mind was his bass guitar. It wasn't just any guitar. It was custom built for Curtis Lee Holbrook, better known as Corky. He is famous for being in ZACHARIAH and then as the bassist of Sly Dog, the band that backed Billy Ray Cyrus as he became a country legend for his first album "Some Gave All." In the early 2000s, he returned to Ashland, Kentucky to make golf clubs and started Thunder Bay Studios to focus on producing records for local artists. In the 1990s, at the height of the popularity of Billy Ray Cyrus, the Fender Guitar company reached out to Corky and offered to build a bass to Corky's specifications — it had the neck of a Jazz Bass, the body of a Precision, electronics identical to a vintage 1962 model and a tobacco sunburst finish that fades from orange to brown to black at the edges. It was marked with the serial number V061100. "It was a hodgepodge of Fender parts and it was absolutely his pride and joy," Lambert said. "He took that on tour with him and it was his go-to bass." Lambert said Corky usually kept his prized bass at home, but took it to the studio one day in 2014 and left it there. Soon after, the bass was stolen. "He didn't even know the exact date it was stolen, because they opened the case, took the bass and left the case behind," Lambert said. "My dad just assumed it was in there until one day when someone asked him what was up with the empty case. He was devastated." For years, Corky tried to track down the guitar, checking pawn shops and even, at one point, offering $3,000 for its return. "I knew it was devastating for him," Lambert said, adding her dad would often go online in an effort to find it. "The bass wasn't even worth more than a couple thousand dollars. But to him, it was worth everything." Lambert said she didn't truly know how much the loss of the bass bothered Corky until the past few months. "He had been really sick and a couple days before his passing, he was in hospice and he mentioned to my aunt how upset he was that he never managed to recover the bass," Lambert said. "He knew he was dying and that was one of his last thoughts." In one of her last phone conversations with her dad, she told him that she loved him and that her best traits came from him including her musical talents. "I just wanted him to know how truly awesome of dad he was. And I made him a promise, I said I was going to find that bass," Lambert said. "My goal is not to get it back for me. My thought is that if I get it back, he can rest in peace. It devastates me that he brought it up on his death bed. It makes me upset that there was 10 years I could have been looking for it while he was still around." Corky passed away on May 14. Less than a week before he passed, Lambert, a violinist who has been learning to play the bass guitar, sent him a video of her playing a version of The Pixies' song "Where is my Mind?" "He watched the video and it brought such joy to his eyes. It was so worth all the time I spent to learn it," Lambert said. "I have always looked up to him and his talent." Lambert has taken to the Internet to bolster the search for that custom bass. She started a thread on Reddit in the r/Bass forum and on She created a computer-generated image of the bass to give people an idea of what it looks like. She even set up a for people to aid in her search. "I don't have any leads yet," she said. "Whoever took it may not even know the sentimental value of it. It could just be sitting in someone's closet. It could be sitting ins someone's pawn shop or used music shop. It is just sitting somewhere and I just want to get it back." You Might Like Lifestyles Villages plan activities around July 4 News Withrow chosen for council seat News Area students named to OU's Spring 2025 President's List News DeWine, mental health leaders unveil 988 license plate
Yahoo
28-05-2025
- Business
- Yahoo
Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032
The AI in precision medicine market is experiencing significant growth, driven by the increasing global prevalence of chronic and genetic disorders, which has heightened the demand for personalized treatment approaches. This growth is further supported by the increasing demand for precision diagnostics and customized therapies that leverage AI's capabilities in analyzing complex biological data. Advancements in AI-driven technologies, along with ongoing innovation in product development, are improving the accuracy and efficiency of precision-based interventions. New York, USA, May 28, 2025 (GLOBE NEWSWIRE) -- Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032 | DelveInsight The AI in precision medicine market is experiencing significant growth, driven by the increasing global prevalence of chronic and genetic disorders, which has heightened the demand for personalized treatment approaches. This growth is further supported by the increasing demand for precision diagnostics and customized therapies that leverage AI's capabilities in analyzing complex biological data. Advancements in AI-driven technologies, along with ongoing innovation in product development, are improving the accuracy and efficiency of precision-based interventions. DelveInsight's AI in Precision Medicine Market Insights report provides the current and forecast market analysis, individual leading AI in precision medicine companies' market shares, challenges, AI in precision medicine market drivers, barriers, trends, and key market AI in precision medicine companies in the market. Key Takeaways from the AI in Precision Medicine Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in precision medicine market during the forecast period. In the product segment of the AI in precision medicine market, the hardware/software category held the largest revenue share in 2024. Notable AI in precision medicine companies such as TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., and several others are currently operating in the AI in precision medicine market. In April 2025, Illumina Inc. and Tempus AI, Inc. partnered to accelerate the clinical adoption of next-generation sequencing tests. By combining Illumina's advanced AI technologies with Tempus's extensive multimodal data platform, the collaboration aims to train genomic algorithms and speed up the use of molecular testing in patient care. In February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic device that uses AI to generate heatmaps to identify small or rare prostatic cancers. In June 2024, a leading medical imaging AI company, received 510(k) clearance from the FDA for CINA-VCF, an AI-powered triage and notification tool designed to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing chest or abdomen CT scans. In March 2024, Bayer and Aignostics entered into a collaboration to advance next-generation precision oncology. Together, they will co-develop a novel target identification platform that utilizes multimodal patient data and cutting-edge AI/ML algorithms to enhance cancer treatment precision. To read more about the latest highlights related to the AI in precision medicine market, get a snapshot of the key highlights entailed in the Global AI in Precision Medicine Market Report AI in Precision Medicine Overview Artificial intelligence (AI) is revolutionizing precision medicine by enabling highly personalized approaches to disease diagnosis, treatment, and prevention. By analyzing vast datasets from genomic sequencing, electronic health records, imaging, and wearable devices, AI algorithms can uncover patterns and biomarkers that are often invisible to human researchers. These insights allow clinicians to identify specific disease subtypes, predict individual patient responses to therapies, and tailor treatments to genetic profiles, thus improving efficacy and reducing adverse effects. In oncology, for instance, AI is helping identify actionable mutations and optimize targeted therapies, bringing more precise interventions to patients. Beyond diagnosis and treatment, AI also plays a crucial role in accelerating drug discovery and development in precision medicine. Machine learning models can predict drug-target interactions, simulate clinical outcomes, and identify suitable patient cohorts for clinical trials, significantly cutting down timelines and costs. Moreover, AI enhances real-time monitoring of patient health through integration with digital health tools, facilitating timely interventions and adaptive treatment strategies. As data grows more complex and voluminous, AI's ability to synthesize, learn, and adapt offers an indispensable advantage in realizing the full potential of precision in Precision Medicine Market Insights North America held the largest share of the AI in precision medicine market from 2025 to 2032. This leading position can be attributed to several key factors, including the increasing prevalence of chronic conditions such as cancer, lifestyle-related illnesses like diabetes, and various infectious diseases. The region also benefits from robust R&D initiatives in AI-driven precision medicine, a well-developed healthcare infrastructure. In addition, major companies in the region are making substantial R&D investments to bring cutting-edge AI-based precision medicine solutions to market. For instance, in April 2024, Prenosis secured FDA De Novo marketing authorization for its Sepsis ImmunoScore™, an AI-powered diagnostic tool that supports precision diagnosis and risk assessment for sepsis. Likewise, in February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an AI-enabled in vitro diagnostic device that generates heatmaps to detect small or rare prostatic cancers, offering a critical diagnostic aid for pathologists. As a result of these combined factors, the AI in precision medicine market is expected to experience significant growth in North America throughout the forecast period. To know more about why North America is leading the market growth in the AI in precision medicine market, get a snapshot of the AI in Precision Medicine Market Outlook AI in Precision Medicine Market Dynamics The AI in precision medicine market is undergoing rapid transformation, driven by the convergence of big data analytics, machine learning, and personalized healthcare. Precision medicine focuses on tailoring medical treatment to the individual characteristics of each patient, and AI enables this by analyzing vast datasets from genomic information to electronic health records to identify patterns, predict outcomes, and guide clinical decisions. This has created significant demand for AI-enabled platforms that can support drug discovery, diagnostics, and treatment planning, especially in oncology, rare diseases, and chronic conditions. Market growth is being accelerated by increasing investments from pharmaceutical companies, biotech startups, and technology giants. These players are leveraging AI to reduce the cost and time of clinical trials, improve target identification, and develop more precise biomarkers. Government initiatives like the U.S. Precision Medicine Initiative and the EU's Digital Health Strategy are also catalyzing adoption by funding R&D and creating regulatory frameworks that support innovation in AI-driven healthcare solutions. As a result, the global market for AI in precision medicine is projected to grow at a strong CAGR through the next decade. Despite these tailwinds, the market faces several challenges. Data privacy and interoperability remain major hurdles, especially given the sensitive nature of health data and the lack of standardized health IT systems across countries and institutions. Moreover, ethical concerns around algorithmic bias, transparency, and patient consent are prompting calls for tighter regulation and governance. Trust in AI systems remains a key barrier to adoption among healthcare professionals, who often require explainable and clinically validated outputs before integrating AI into routine practice. Nevertheless, the competitive landscape is vibrant. Major tech firms are partnering with hospitals and research institutions to advance AI-driven care models. Startups focusing on niche applications, such as AI-powered pathology, genomic interpretation, and personalized oncology treatments, are also attracting significant venture capital. As the ecosystem matures, we can expect increasing consolidation and the emergence of integrated platforms that bridge diagnostics, therapeutics, and decision support, further driving market expansion. Get a sneak peek at the AI in precision medicine market dynamics @ AI in Precision Medicine Market Dynamic Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Precision Medicine Market CAGR ~33% AI in Precision Medicine Market Size by 2032 USD 10.2 Billion Key AI in Precision Medicine Companies TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others AI in Precision Medicine Market Assessment AI in Precision Medicine Market Segmentation AI in Precision Medicine Market Segmentation By Product: Hardware/Software and Services AI in Precision Medicine Market Segmentation By Technology: Deep Learning, Natural Language Processing, and Machine Learning AI in Precision Medicine Market Segmentation By Application: Drug Discovery & Development and Disease Diagnostics AI in Precision Medicine Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others AI in Precision Medicine Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the AI in precision medicine market are set to emerge as the trendsetter explore @ AI in Precision Medicine Companies Table of Contents 1 AI in Precision Medicine Market Report Introduction 2 AI in Precision Medicine Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Precision Medicine Market Key Factors Analysis 6 AI in Precision Medicine Market Porter's Five Forces Analysis 7 AI in Precision Medicine Market Layout 8 AI in Precision Medicine Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the AI in precision medicine market by 2032? Click to get a snapshot of the AI in Precision Medicine Market Trends Related Reports Artificial Intelligence in Drug Commercialization Market Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others. Artificial Intelligence in Clinical Trials Market Artificial Intelligence in Clinical Trials Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in clinical trials companies, including TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others. Artificial Intelligence In Drug Discovery Market Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others. Artificial Intelligence in Medical Imaging Market Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others. Artificial Intelligence in Life Sciences Market Artificial Intelligence in Life Sciences Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in life sciences companies, including IBM Corporation, Atomwise, Inc., Nuance Communications, Inc., NuMedii, Inc., AiCure LLC, APIXIO, Inc., Insilico Medicine, Inc., Enlitic, Inc., Sensely, Inc., Zebra Medical Vision, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679 in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Europe Precision Medicine Market Research Report 2024-2034, Competitive Analysis of Almac Group, ANGLE, F. Hoffmann-La Roche, Merck, and QIAGEN
Advances in genomes, diagnostics, and targeted medicines are driving the precision medicine sector in Europe. Key factors include the growing prevalence of chronic diseases, the integration of digital health resources, and an increased emphasis on personalised healthcare. The creation of customised medicines is being aided by government programs and research partnerships, which is increasing patient results. Furthermore, the care of uncommon illnesses, cardiology, and oncology is changing due to the extensive use of biomarkers, next-generation sequencing, and AI-powered diagnostics. Precision medicine is being adopted more quickly in a variety of healthcare settings thanks to the region's robust healthcare infrastructure and rising awareness of personalised treatment. European Precision Medicine Market Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Europe Precision Medicine Market: Focus on Ecosystem and Country - Analysis and Forecast, 2024-2034" report has been added to Europe precision medicine market is projected to reach $118.79 billion by 2034 from $40.75 billion in 2024, at a CAGR of 11.29% during the forecast period of 2024-2034. From one-size-fits-all therapies to highly customised therapeutic options, the precision medicine market in Europe is drastically changing the healthcare environment. More specialised methods of diagnosing and treating diseases have been made possible by technological advancements, especially in the fields of genomics, next-generation sequencing, and biomarker identification. Personalised therapies are greatly improving patient outcomes in uncommon genetic disorders, cardiovascular diseases, and oncology. By promoting policies that are helpful and making significant investments in research and development, European governments have been instrumental in this change. While maintaining strict guidelines for patient privacy and data security, regulatory bodies are expediting the approval procedures for precision market is further bolstered by strategic alliances among pharmaceutical companies, biotech firms, and academic institutions, fostering an ecosystem of innovation and collaborative research. Digital health tools and artificial intelligence are increasingly integrated into clinical workflows, enhancing diagnostic accuracy and treatment customization. Despite challenges such as the high cost of advanced technologies, regulatory complexities, and the need for robust healthcare infrastructure, the momentum behind precision medicine remains strong. Europe's commitment to personalized healthcare, underpinned by public funding and private investment, positions the region as a global leader in redefining clinical practices and delivering patient-centric Trends, Drivers and Challenges of Europe Precision Medicine MarketAdvances in genetics, artificial intelligence, and health technology that allow for individualised treatment options are driving a rapid evolution of the precision medicine business in Europe. Especially in oncology and uncommon disorders, the combination of next-generation sequencing and biomarker development is promoting early detection and focused treatments. The market is expanding thanks to government programs, more financing for healthcare innovation, and cooperative research activities. The market is expanding due to ageing populations, an increase in the prevalence of chronic diseases, and a need for more efficient treatment plans. However, obstacles to wider adoption include expensive costs, intricate legal frameworks, and data privacy issues. It takes large infrastructure investments and patient education to incorporate precision medicine into traditional healthcare systems. Notwithstanding these obstacles, technological developments and strategic alliances between biotech, pharmaceutical, and academic organisations are opening the door to a more cohesive and effective precision medicine ecosystem, which will eventually lead to better patient outcomes and a shift in Europe towards individualised healthcare Market Players Almac Group ANGLE plc F. Hoffmann-La Roche Ltd. Merck KGaA QIAGEN N.V. bioMerieux SA Sanofi S.A. Randox Laboratories Ltd. GSK plc Novartis AG Menarini Silicon Biosystems Key Attributes: Report Attribute Details No. of Pages 83 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $40.75 Billion Forecasted Market Value (USD) by 2034 $118.79 Billion Compound Annual Growth Rate 11.2% Regions Covered Europe Key Topics Covered: 1 Market Overview1.1 Market Definition1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy1.4 Initiatives and Programs1.5 Precision Medicine: Enabling Technologies and Applications1.5.1 Innovators1.5.1.1 3D DNA Printing1.5.1.1.1 Introduction1.5.1.1.2 Role of 3D DNA Printing1.5.1.2 RNA-Seq1.5.1.2.1 Introduction1.5.1.2.2 Role of RNA-Seq in Precision Medicine1.5.1.2.3 Key Players1.5.1.3 4D Molecular Imaging1.5.1.3.1 Introduction1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine1.5.1.3.3 Key Players1.5.2 Early Adopters1.5.2.1 CRISPR1.5.2.1.1 Introduction1.5.2.1.2 Role of CRISPR in Precision Medicine1.5.2.1.3 Key Players1.5.2.2 Blockchain1.5.2.2.1 Introduction1.5.2.2.2 Role of Blockchain in Precision Medicine1.5.2.2.3 Key Players1.5.2.3 Imaging Informatics1.5.2.3.1 Introduction1.5.2.3.2 Role of Imaging Informatics in Precision Medicine1.5.2.3.3 Key Players1.5.3 Early Majority1.5.3.1 Artificial Intelligence (AI)1.5.3.1.1 Introduction1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine1.5.3.1.3 Key Players1.5.3.2 Circulating Free DNA (cfDNA)1.5.3.2.1 Introduction1.5.3.2.2 Role of cfDNA in Precision Medicine1.5.3.2.3 Key Players1.5.3.3 Big Data1.5.3.3.1 Introduction1.5.3.3.2 Role of Big Data in Precision Medicine1.5.3.3.3 Key Players1.5.3.4 Next-Generation Sequencing (NGS)1.5.3.4.1 Introduction1.5.3.4.2 Role of NGS in Precision Medicine1.5.3.4.3 Key Players1.5.3.5 Health Informatics1.5.3.5.1 Introduction1.5.3.5.2 Role of Health Informatics in Precision Medicine1.5.3.5.3 Key players1.5.3.6 Bioinformatics1.5.3.6.1 Introduction1.5.3.6.2 Role of Bioinformatics in Precision Medicine1.5.3.6.3 Key Players1.5.4 Late Majority1.5.4.1 Polymerase Chain Reactions (PCR)1.5.4.1.1 Introduction1.5.4.1.2 Role of PCR in Precision Medicine1.5.4.1.3 Key players1.5.4.2 Microarray1.5.4.2.1 Role of Microarray in Precision Medicine1.5.4.2.2 Key Players2 Market: Industry Outlook2.1 Precision Medicine Market: Ecosystem Analysis2.2 Market Trends2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine2.3 Industry Insights2.3.1 Patent Analysis2.3.2 Pipeline Analysis2.3.3 Legal Requirements and Framework by the EMA2.4 Ecosystem Summary3 Region3.1 Overview3.2 Europe3.2.1 Regional Overview3.2.2 Driving Factors for Market Growth3.2.3 Factors Challenging the Market3.2.3.1 Europe Precision Medicine Market (by Ecosystem)3.2.4 Germany3.2.4.1 Germany Precision Medicine Market (by Ecosystem)3.2.5 France3.2.5.1 France Precision Medicine Market (by Ecosystem)3.2.6 Italy3.2.6.1 Italy Precision Medicine Market (by Ecosystem)3.2.7 U.K.3.2.7.1 U.K. Precision Medicine Market (by Ecosystem)3.2.8 Spain3.2.8.1 Spain. Precision Medicine Market (by Ecosystem)3.2.9 Rest-of-Europe3.2.9.1 Rest-of-Europe Precision Medicine Market (by Ecosystem)4 Competitive Landscape4.1 Competitive Landscape4.1.1 Synergistic Activities4.2 Company Profiles4.2.1 Overview4.2.2 Top Products/Services4.2.3 Top Competitors4.2.4 Analyst ViewFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Precision Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Why Deere (DE) Stock Is Up Today
Shares of agricultural and construction machinery company Deere (NYSE:DE) jumped 5% in the morning session after the company turned in an impressive second quarter, with both sales and earnings beating expectations, even though sales overall were down quite a bit from the previous year. The company managed to hold the line on margins and showed it could still deliver in a tough market. Sales in its big farming segment, Production & Precision Ag, dropped 21%. But the margin was still solid at 22%. Over in Small Ag & Turf, revenue dipped 6%, but profits edged higher. That margin strength gave earnings a nice lift, and EPS came in above forecasts. Deere largely didn't change its full-year outlook, but it did say Small Ag & Turf could be a bit weaker than expected. Overall, this was a mixed yet decent quarter. Is now the time to buy Deere? Access our full analysis report here, it's free. Deere's shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock gained 8.5% on the news that the company reported impressive third-quarter 2024 results that exceeded analysts' revenue and EPS estimates. Looking ahead, the company initiated fiscal 2025 guidance, calling for revenues down 10-15% year on year. While this felt like a negative, it revealed that end markets were not getting worse and might be reaching a trough. Zooming out, we think this was a good quarter with guidance showing that demand may be hitting a bottom in 2025 and poised for an uptick thereafter, especially if themes like reshoring and industrial automation become more real. Deere is up 25% since the beginning of the year, and at $522.67 per share, has set a new 52-week high. Investors who bought $1,000 worth of Deere's shares 5 years ago would now be looking at an investment worth $4,148. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Why Deere (DE) Stock Is Up Today
Shares of agricultural and construction machinery company Deere (NYSE:DE) jumped 5% in the morning session after the company turned in an impressive second quarter, with both sales and earnings beating expectations, even though sales overall were down quite a bit from the previous year. The company managed to hold the line on margins and showed it could still deliver in a tough market. Sales in its big farming segment, Production & Precision Ag, dropped 21%. But the margin was still solid at 22%. Over in Small Ag & Turf, revenue dipped 6%, but profits edged higher. That margin strength gave earnings a nice lift, and EPS came in above forecasts. Deere largely didn't change its full-year outlook, but it did say Small Ag & Turf could be a bit weaker than expected. Overall, this was a mixed yet decent quarter. Is now the time to buy Deere? Access our full analysis report here, it's free. Deere's shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock gained 8.5% on the news that the company reported impressive third-quarter 2024 results that exceeded analysts' revenue and EPS estimates. Looking ahead, the company initiated fiscal 2025 guidance, calling for revenues down 10-15% year on year. While this felt like a negative, it revealed that end markets were not getting worse and might be reaching a trough. Zooming out, we think this was a good quarter with guidance showing that demand may be hitting a bottom in 2025 and poised for an uptick thereafter, especially if themes like reshoring and industrial automation become more real. Deere is up 25% since the beginning of the year, and at $522.67 per share, has set a new 52-week high. Investors who bought $1,000 worth of Deere's shares 5 years ago would now be looking at an investment worth $4,148. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
